OUR THERAPEUTIC AREAS
We are a major global player in cardiometabolism and in the treatment of venous diseases. In oncology, we are developing precision therapies for rare forms of cancer. In neurology, our objective is to develop therapeutic solutions for patients with rare neurological disorders. Our research focuses on indications with high unmet needs.
ONCOLOGY
Cancer causes more than one in six of all deaths, making it the second leading cause of death throughout the world¹. To address the growing need for therapeutic solutions, we allocate nearly 70% of our R&D budget to oncology. Our objective is to develop precision therapies that aim to transform the lives of patients affected by cancer. We are a focused and innovative player in the treatment of digestive cancers, brain tumors and hematological cancers.
NEUROLOGY
Rare neurological disorders affect between 130 and 220 million people worldwide²; approximately 600 rare neurological conditions have been identified³. At Servier, we focus on discovering new medicines that slow or halt disease progression in rare neurological disorders and significantly improve patient quality of life. To reach this goal, we are building on our core areas of expertise: small molecules, monoclonal antibodies and antisense oligonucleotides (ASOs). That’s why we have defined six clusters of diseases to concentrate on: rare refractory epilepsies, rare movement disorders, neuromuscular disorders, genetically-driven autism spectrum disorders (ASD), leukodystrophies and peripheral neuropathies.
CARDIOMETABOLISM AND VENOUS DISEASES
Cardiovascular diseases and their complications are the leading cause of death worldwide: with 19.8 million deaths in 2022, they represent one third of total global mortality 5 .
In this area, we take a holistic, patient-centered approach. As the world’s leading pharmaceutical group in hypertension and ranking fifth in cardiology 4 , our objective is to innovate in order to transform the lives of people living with chronic diseases. We accomplish this in particular through Single Pill Combinations (SPCs), which combine several medicines into a single tablet. We also develop innovative digital services to improve therapeutic adherence.
References
1. World Health Organization (WHO), Cancer – Fact sheet, February 2022.
2. Mancuso M. et al., Neurological Sciences, 2020.
3. Neurological Disorders Market, DelveInsight Business Research, January 2025.
4. IQVIA, Analytics Link / World, 84 countries – MAT Q3-2025.
5. World Health Organization (WHO), Diabetes – Fact sheet, November 2024.
